Abstract: The present invention relates to the identification of polypeptides, proteins and protein isoforms that are associated with breast cancer and its onset and development, and of genes encoding the same, and to their use for e.g., clinical screening, diagnosis, prognosis, therapy and prophylaxis, as well as for drug screening and drug development.

Abstract: The present invention relates to the identification of polypeptides, proteins and protein isoforms that are associated with ErbB-2 related cancer and its onset and development, of genes encoding the same, and to their use for e.g., clinical screening, diagnosis, prognosis, therapy and prophylaxis, as well as for drug screening and drug development.

Abstract: The present invention provides methods and compositions for screening, diagnosis and prognosis of Schizophrenia, for monitoring the effectiveness of Schizophrenia treatment, identifying patients most likely to respond to a particular therapeutic treatment and for drug development. Schizophrenia-Associated Features (SFs), detectable by two-dimensional electrophoresis of cerebrospinal fluid, serum or plasma are described. The invention further provides Schizophrenia-Associated Protein Isoforms (SPIs) detectable in cerebrospinal fluid, serum or plasma, preparations comprising isolated SPIs, antibodies immunospecific for SPIs, and kits comprising the aforesaid.

Abstract: The present invention provides methods and compositions for screening, diagnosis and prognosis of Alzheimer's disease, for monitoring the effectiveness of Alzheimer's disease treatment, and for drug development. Alzheimer's Disease-Associated Features (AFs), detectable by two-dimensional electrophoresis of cerebrospinal fluid, serum or plasma are described. The invention further provides Alzheimer's Disease-Associated Protein Isoforms (APIs) detectable in cerebrospinal fluid, serum or plasma, preparations comprising isolated APIs, antibodies immunospecific for APIs, pharmaceutical compositions, diagnostic and therapeutic methods, and kits comprising or based on the same.

Abstract: The present invention provides methods and compositions for screening, diagnosing and prognosing liver response, for monitoring the effectiveness of liver response treatment, and for drug development.

Abstract: The present invention provides a protein (DPI-6) identified in CSF, compositions comprising the protein, including vaccines and antibodies which are immunospecific for the protein. The use of the protein in the diagnosis, screening, treatment and prophylaxis of a neurological or neuropsychiatric condition is also provided.

Abstract: The present invention provides methods and compositions for screening, diagnosis and prognosis of breast cancer, for monitoring the effectiveness of breast cancer treatment, and for drug development. Breast Cancer-Associated Features (BFs), detectable by two-dimensional electrophoresis of serum are described. The invention further provides Breast Cancer-Associated Protein Isoforms (BPIs) detectable in cerebrospinal fluid, serum or plasma, preparations comprising isolated BPIs, antibodies immunospecific for BPIs, and kits comprising the aforesaid.

Abstract: The present invention provides a protein (ADPI-41) identified in brain tissue, compositions comprising the protein, including vaccines and antibodies, which are immunospecific for the protein. The use of the protein in the diagnosis, screening, treatment and prophylaxis of Alzheimer's disease is also provided.

Abstract: The present invention relates to the identification of proteins and protein isoforms that are associated with breast cancer and its onset and development, and of genes encoding the same, and to their use for e.g., clinical screening, diagnosis, prognosis, therapy and prophylaxis, as well as for drug screening and development of pharmaceutical products.

Abstract: The present invention provides methods and compositions for screening, diagnosis and prognosis of Alzheimer's disease, for monitoring the effectiveness of Alzheimer's disease treatment and for drug development. Alzheimer's disease-Associated Features (ADFs) detectable by two-dimensional electrophoresis of brain tissue are described. The invention further provides Alzheimer's disease-Associated Protein Isoforms (ADPIs) detectable in brain tissue, preparations comprising isolated ADPIs, antibodies specific for ADPIs and kits comprising the aforesaid.

Abstract: The present invention provides methods and compositions for screening, diagnosis and prognosis of BAD, for monitoring the effectiveness of BAD treatment, and for drug development. BAD-Associated Features (DFs), detectable by two-dimensional electrophoresis of cerebrospinal fluid, serum or plasma are described. The invention further provides BAD-Associated Protein Isoforms (DPIs) detectable in cerebrospinal fluid, serum or plasma, preparations comprising isolated DPIs, antibodies immunospecific for DPIs, and kits comprising the aforesaid.

Abstract: The present invention provides methods and compositions for screening, diagnosis and prognosis of BAD, for monitoring the effectiveness of BAD treatment, and for drug development. BAD-Associated Features (DFs), detectable by two-dimensional electrophoresis of cerebrospinal fluid, serum or plasma are described. The invention further provides BAD-Associated Protein Isoforms (DPIs) detectable in cerebrospinal fluid, serum or plasma, preparations comprising isolated DPIs, antibodies immunospecific for DPIs, and kits comprising the aforesaid.

Abstract: The present invention provides methods and compositions for screening, diagnosis and prognosis of Alzheimer's disease, for monitoring the effectiveness of Alzheimer's disease treatment, and for drug development. Alzheimer's Disease-Associated Features (AFs), detectable by two-dimensional electrophoresis of cerebrospinal fluid, serum or plasma are described. The invention further provides Alzheimer's Disease-Associated Protein Isoforms (APIs) detectable in cerebrospinal fluid, serum or plasma, preparations comprising isolated APIs, antibodies, pharmaceutical compositions, diagnostic and therapeutic methods, and kits comprising or based on the same.

Abstract: The present invention provides methods and compositions for screening, diagnosis and prognosis of Schizophrenia, for monitoring the effectiveness of Schizophrenia treatment, identifying patients most likely to respond to a particular therapeutic treatment and for drug development. Schizophrenia-Associated Features (SFs), detectable by two-dimensional electrophoresis of cerebrospinal fluid, serum or plasma are described. The invention further provides Schizophrenia-Associated Protein Isoforms (SPIs) detectable in cerebrospinal fluid, serum or plasma, preparations comprising isolated SPIs, antibodies immunospecific for SPIs, and kits comprising the aforesaid.